Article Text

Download PDFPDF

Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease
Free

Statistics from Altmetric.com


 
 Q In patients with Alzheimer’s disease (AD), does donepezil delay entry to institutional care or progression of disability?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Neurology ★★★★★★☆ Geriatrics ★★★★★★☆

METHODS

Embedded ImageDesign:

randomised controlled trial (AD2000 study).

Embedded ImageAllocation:

{concealed*}.

Embedded ImageBlinding:

blinded {patients, healthcare providers, data collectors, and outcome assessors}.*

Embedded ImageFollow up period:

3 years.

Embedded ImageSetting:

22 hospitals in the UK.

Embedded ImagePatients:

566 patients (59% women, median age 75–76 y) who were referred to memory clinics with a suspected DSM-IV diagnosis of dementia of Alzheimer type, with or without coexisting vascular dementia; had a regular carer; lived in the community; were not taking a cholinesterase inhibitor; and had no contraindications to donepezil.

Embedded ImageIntervention:

during a 12 week run in period, patients were allocated to donepezil, 5 mg/day (n = 283), or …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.